Secondary endpoints: improvement in lupus activity scores (SLEDAI and BILAG), complement concentration, anti-dsDNA antibody and ANA titres, death and commencement of permanent dialysis or renal transplantation. Here, BTG3 is linked to systemic lupus erythematosus.